Skip to content

Efficacy Testing of Collagen Elixir

Efficacy Testing of Collagen Drink

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04878536
Enrollment
60
Registered
2021-05-07
Start date
2021-05-18
Completion date
2021-10-25
Last updated
2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Condition

Brief summary

To assess Isagenix-Collagen Elixir on skin condition improvement

Interventions

DIETARY_SUPPLEMENTCollagen drink

Testing product

DIETARY_SUPPLEMENTBlank

Placebo drink

Sponsors

TCI Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy adults aged above 20 years old

Exclusion criteria

* Subject who is not willing to participate in this study. * Patients with diseases of the skin, liver, kidney. * Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder. * Female who is pregnant or nursing or planning to become pregnant during the course of the study. * Received facial laser therapy, chemical peeling or UV overexposure in the past 4 weeks. * Constant drug use * Participated cosmetic product human study in the past 3 months.

Design outcomes

Primary

MeasureTime frameDescription
The change of TIMP-1 of bloodChange from Baseline TIMP-1 at 4 weeksVenous blood was sampled to measure TIMP-1
The change of MMP-1 of bloodChange from Baseline MMP-1 at 4 weeksVenous blood was sampled to measure MMP-1
The change of skin elasticityChange from Baseline skin elasticity at 4 weeksSoft Plus was utilized to measure skin elasticity. Units: arbitrary units
The change of skin collagen densityChange from Baseline skin collagen density at 4 weeksDermaLab® Series SkinLab Combo was utilized to measure skin pores. Units: arbitrary units
The change of skin textureChange from Baseline skin texture at 4 weeksVISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units
The change of skin wrinklesChange from Baseline skin wrinkles at 4 weeksVISIA Complexion Analysis System was utilized to measure skin wrinkles. Units: arbitrary units

Secondary

MeasureTime frameDescription
The change of skin brown spotsChange from Baseline skin brown spots at 4 weeksVISIA Complexion Analysis System was utilized to measure skin brown spots. Units: arbitrary units
The change of TNF-α of bloodChange from Baseline TNF-α at 4 weeksVenous blood was sampled to measure TNF-α
The change of skin melanin indexChange from Baseline skin melanin index at 4 weeksSoft Plus was utilized to measure skin melanin index. Units: arbitrary units
The change of skin L* valueChange from Baseline L* value at 4 weeksChroma Meter MM500 was utilized to measure skin L\* value. Units: arbitrary units, 0-100
The change of skin moistureChange from Baseline skin moisture at 4 weeksCorneometer® CM825 was utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120
The change of skin spotsChange from Baseline skin spots at 4 weeksVISIA Complexion Analysis System was utilized to measure skin spots. Units: arbitrary units
The change of skin UV spotsChange from Baseline skin UV spots at 4 weeksVISIA Complexion Analysis System was utilized to measure skin UV spots. Units: arbitrary units
The change of IL-10 of bloodChange from Baseline IL-10 at 4 weeksVenous blood was sampled to measure IL-10
The change of SOD-RBC of bloodChange from Baseline SOD-RBC at 4 weeksVenous blood was sampled to measure SOD-RBC
The change of f-thiols of bloodChange from Baseline f-thiols at 4 weeksVenous blood was sampled to measure f-thiols
The change of t-GSH of bloodChange from Baseline t-GSH at 4 weeksVenous blood was sampled to measure t-GSH
The change of GST-RBC of bloodChange from Baseline GST-RBC at 4 weeksVenous blood was sampled to measure GST-RBC
The change of MDA of bloodChange from Baseline MDA at 4 weeksVenous blood was sampled to measure MDA
The change of blood total antioxidant capacity (TAC)Change from Baseline TAC at 4 weeksVenous blood was sampled to measure concentrations of TAC

Other

MeasureTime frameDescription
The change of total cholesterol of bloodChange from Baseline total cholesterol at 4 weeksVenous blood was sampled to measure total cholesterol
The change of triglyceride of bloodChange from Baseline triglyceride at 4 weeksVenous blood was sampled to measure triglyceride
The change of uric acid of bloodChange from Baseline uric acid at 4 weeksVenous blood was sampled to measure uric acid
The change of creatinine of bloodChange from Baseline creatinine at 4 weeksVenous blood was sampled to measure creatinine
The change of BUN of bloodChange from Baseline BUN at 4 weeksVenous blood was sampled to measure BUN
The change of SGPT of bloodChange from Baseline SGPT at 4 weeksVenous blood was sampled to measure SGPT
The change of SGOT of bloodChange from Baseline SGOT at 4 weeksVenous blood was sampled to measure SGOT

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026